All In Biotech

Drug Trial Radar · NCT07229612

A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors

A Multicenter, Open-label Phase I/II Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-4298 Injection in Patients With Malignant Solid Tumors

Last checked: Nov 19, 2026Latest source record: Aug 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 3, 2025

Primary completion

Nov 2028

Study completion Nov 2028

Sponsor

Sponsor type
Industry
First posted
Nov 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-4298 injection in patients with malignant solid tumors.

Conditions

  • Malignant Solid Tumors

Interventions

  • SHR-4298 InjectionDrug

    SHR-4298 injection.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs).Time frame: Approximately 18 months.
  2. Incidence and severity of serious adverse events (SAEs).Time frame: Approximately 18 months.
  3. Maximum Tolerated Dose (MTD).Time frame: Approximately 18 months.
  4. Maximum Applicable Dose (MAD).Time frame: Approximately 18 months.
  5. Recommended Phase 2 Dose (RP2D).Time frame: Approximately 18 months.
  6. Dose-limiting toxicity (DLT).Time frame: Approximately 18 months.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.